TCL Archive New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years October 26, 2012
TCL Archive NTP Committee Finds Five Test Reports Show “Limited” Evidence Of Carcinogenicity February 27, 1981
TCL Archive Phase III Data of Antibody-Drug Conjugate Shows PFS Increase in HER2+ Disease June 29, 2012